Zlatarova Zornitsa, Hristova Elitsa, Bliznakova Kristina, Atanasova Virginia, Yaneva Zhaneta, Koseva Darina, Zaduryan Lidiya, Vasileva Gabriela, Stefanova Daliya, Dokova Klara
Department of Optometry and Occupational Diseases, Medical University of Varna, 9002 Varna, Bulgaria.
University Specialized Eye Hospital, 9002 Varna, Bulgaria.
Diagnostics (Basel). 2024 Oct 21;14(20):2340. doi: 10.3390/diagnostics14202340.
Diabetic retinopathy (DR) is a leading cause of visual impairment globally among working-aged individuals. This study aims to update data on DR prevalence in Bulgaria.
The present cross-sectional study was conducted between 1 January 2022 and 1 January 2023, using a local diabetes registry from the city of Varna as a sampling framework. In total, 587 diabetic patients underwent DR examination. Data included demographics, diabetes type/duration, treatment, and ophthalmic history. DR status was assessed using indirect slit-lamp biomicroscopy or digital fundus photography, graded by the International Clinical Diabetic Retinopathy Scale.
Of 587 participants, 13 were excluded due to cataract-related ungradable images. The median age was 65 years (IQR 56-73), with a slight female predominance (54%). The overall prevalence of any DR was 39.9% (95% CI 35.9-44.0), with non-proliferative DR (NPDR) at 27.5%, proliferative DR (PDR) at 7.3%, and macular edema (DME) at 5%. Type 1 diabetes patients had significantly higher DR prevalence (68.8%) than type 2 (34.1%, < 0.001). Men exhibited higher DR prevalence. Age and diabetes duration correlated positively with DR prevalence. Insulin treatment was associated with higher DR prevalence (55.6%) than oral antidiabetic treatment (22.5%, < 0.001) for type 2 diabetes patients. Among those diagnosed with DR, 70.9% received treatment, mainly laser therapy.
These findings provide epidemiological insights for future research and emphasize the need for a comprehensive national DR screening program in Bulgaria. Technological advancements enable proactive measures to mitigate DR-related visual impairment and blindness, including widespread screening, even in rural areas.
糖尿病视网膜病变(DR)是全球工作年龄人群视力损害的主要原因。本研究旨在更新保加利亚DR患病率的数据。
本横断面研究于2022年1月1日至2023年1月1日进行,以瓦尔纳市的当地糖尿病登记册作为抽样框架。共有587名糖尿病患者接受了DR检查。数据包括人口统计学、糖尿病类型/病程、治疗情况和眼科病史。使用间接裂隙灯生物显微镜或数字眼底摄影评估DR状态,并根据国际临床糖尿病视网膜病变分级标准进行分级。
587名参与者中,13人因白内障相关无法分级的图像被排除。中位年龄为65岁(四分位间距56 - 73岁),女性略占优势(54%)。任何DR的总体患病率为39.9%(95%可信区间35.9 - 44.0),其中非增殖性DR(NPDR)为27.5%,增殖性DR(PDR)为7.3%,黄斑水肿(DME)为5%。1型糖尿病患者的DR患病率(68.8%)显著高于2型糖尿病患者(34.1%,P < 0.001)。男性的DR患病率更高。年龄和糖尿病病程与DR患病率呈正相关。对于2型糖尿病患者,胰岛素治疗的DR患病率(55.6%)高于口服降糖治疗(22.5%,P < 0.001)。在诊断为DR的患者中,70.9%接受了治疗,主要是激光治疗。
这些发现为未来研究提供了流行病学见解,并强调保加利亚需要一个全面的全国DR筛查项目。技术进步使人们能够采取积极措施减轻与DR相关的视力损害和失明,包括广泛筛查,即使在农村地区也是如此。